[News] COVID-19 Vaccine: What are the requirements to apply for Phase 3 trials in Peru?

[Dr.Drako]

Dr. Germán Málaga, professor of medicine at the Cayetano Heredia University, shared the list of requirements for those who want to participate as volunteers in phase 3 clinical trials of the Sinopharm company vaccine in Peru.
President Martín Vizcarra announced that six thousand Peruvians will participate in phase 3 clinical trials of the vaccine made in China by the Sinopharm company.

 

In conversation with Dr. Elmer Huerta, the main professor of Medicine at the Universidad Peruana Cayetano Heredia (UPCH), German Málaga, provided more information on what the requirements will be to be part of this study.

As recalled, a first group of 3,000 people will participate in trials with the UPCH and another group of 3,000 will do so with the Universidad Nacional Mayor de San Marcos (UNMSM).

 

Malaga specified that a group of 2,000 people will receive the Wuhan virus strain vaccine, another group of 2,000 other members will be injected with the Beijing virus strain and another 2,000 will undergo the placebo effect.

What requirements must I meet?
Dr. Málaga reported that the minimum age to participate will be 18 years and the maximum 75. He also indicated that those patients who are currently undergoing some medicated treatment or with uncontrolled diseases such as tuberculosis will be discarded.

 

"If you have hypertension, but it is controlled, there is no problem for you to participate," said Malaga. Likewise, he pointed out that all those selected will undergo COVID-19 discard swab tests and blood tests to rule out any other disease.

If the volunteer develops any symptoms after being injected with the vaccine, he or she will have health insurance with coverage of up to $ 500,000.

 

To register as a volunteer, Dr. Málaga indicated that it can be done through vaccinecovid.pe which will be activated this Wednesday, August 26. "We intend that we can recruit volunteers before September 8," he said.
Newsletter All about the coronavirus
COVID-19 has put everyone on alert. Subscribe to our newsletter All about the coronavirus, where you will find the most relevant daily data in the country and the world on the advance of the virus and the fight against its spread.